Seres Therapeutics Inc (MCRB)

[Digger 2-0]

Equities research analysts at HC Wainwright initiated coverage on shares of Seres Therapeutics Inc. (NASDAQ:MCRB) in a research report issued to clients and investors on Friday. The brokerage set a “buy” rating and a $50.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 39.78% from the company’s current price.

Seres Therapeutics (NASDAQ:MCRB) opened at 35.77 on Friday. The company’s market cap is $1.41 billion. The firm has a 50-day moving average price of $31.41 and a 200 day moving average price of $28.23. Seres Therapeutics has a 12 month low of $21.12 and a 12 month high of $52.00.

Seres Therapeutics (NASDAQ:MCRB) last posted its earnings results on Monday, May 16th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.02. The firm earned $2.71 million during the quarter, compared to the consensus estimate of $1.25 million. On average, equities analysts expect that Seres Therapeutics will post ($1.81) earnings per share for the current year.

http://www.americanbankingnews.com/2016/07/29/seres-therapeutics-inc-mcrb-research-coverage-started-at-hc-wainwright/